Introduction {#s1}
============

Tuberculosis (TB) is the ninth leading cause of death worldwide and the leading cause from a single infectious agent, with 1.3 million deaths and 10.4 million new cases worldwide in 2016 (WHO, [@B33]). Accurate and early diagnosis is important for controlling infection and effective treatment of TB. The current conventional methods for TB diagnosis are primarily smears for acid-fast bacilli (AFB) and *Mycobacterium tuberculosis* culture (Kranzer et al., [@B16]). However, the AFB smear positivity rate among TB cases was found to be only 20--30%, and the culture requires 4--8 weeks for the growth of *M. tuberculosis* (Dheda et al., [@B6]). New automatic molecular methods, such as GeneXpert MTB/RIF for the diagnosis of TB, are currently available; however, the cost is too high for resource-limited settings without committed long-term, external funding (Albert et al., [@B3]; García-Basteiro et al., [@B10]). Therefore, identifying appropriate molecular biomarkers for early diagnosis of TB is in urgent need.

Circular RNAs (circRNAs) are a novel class of RNAs that participate in several physiological and pathological processes (Liu et al., [@B21]; Ng et al., [@B25]). Growing evidence has suggested that many circRNAs can function as competing endogenous (ceRNAs) RNAs to block the functions of their target microRNAs (miRNAs) by binding target miRNAs, a mechanism called miRNA sponging (Kulcheski et al., [@B17]; Rong et al., [@B29]). Different from linear RNAs, circRNAs form a circular structure closed by covalent bonds, with high stability; therefore, many circRNAs can resist RNase digestion to survive in peripheral blood, interstitial fluid and saliva (Memczak et al., [@B23]). Recent researches have shown that circRNAs can serve as molecular biomarkers in the diagnosis and prognosis of many diseases. For example, Zhao et al. found that hsa_circ_0001275 in peripheral blood mononuclear cells (PBMCs) can be used to diagnose postmenopausal osteoporosis (Zhao et al., [@B37]), whereas Li et al. demonstrated that four plasma circRNAs (hsa_circ_102584, hsa_circ_400011, hsa_circ_101471 and hsa_circ_100226) can be used as diagnostic biomarkers of systemic lupus erythematosus (Li et al., [@B19]). Furthermore, Yin et al. reported that plasma hsa_circ_0001785 acts as a diagnostic biomarker for breast cancer detection (Yin et al., [@B35]). Despite increasing evidence that circRNAs widely participate in human diseases exist, the role of circRNAs in TB patients is largely unknown. Our previous study revealed some circRNAs were differentially expressed in the PBMCs between TB patients and healthy controls (Huang et al., [@B14]). In this study, the differentially expressed circRNAs in the plasma of TB patients were screened in a new cohort of subjects, the roles of plasma circulating circRNAs as novel biomarkers for active TB diagnosis were also investigated.

Materials and methods {#s2}
=====================

Patients and plasma collection
------------------------------

Patients (*n* = 173) with active pulmonary TB were consecutively enrolled from the First Affiliated Hospital of Nanchang University and Jiangxi Chest Hospital, China, between May 2015 and January 2017. All TB cases were clinically diagnosed and confirmed as active pulmonary TB by positive AFB smear staining or sputum culture. The patients were then grouped by case severity, including minimal, moderate, and advanced disease stages based on chest radiology (Abakay et al., [@B1]). Each X-ray was scored independently by two different clinicians. In case of divergent opinions, the score was decided by both after discussion. If the disagreement persisted after discussion, a third senior clinician was invited for decision making. The subjects with other co-morbidities were excluded. Then, 25 hospitalized cases with active pulmonary TB were administered a 2HRZE/4HR regimen, starting with 2-month combinatory therapy with rifampicin (RMP, R), isoniazid (INH, H), pyrazinamide (PZA, Z) and ethambutol (EMB, E), followed by HR administration for 4 months. Then, the treated subjected were assessed based on symptoms, bacterial presence and radiological evaluation, and all 25 showed full recovery. Healthy controls (*n* = 153) seeking annual check-up, without clinical diagnosis of any infectious disease, diabetes and malignancy, and no close contact with tuberculosis patients, were randomly enrolled from outpatient clinics of the First Affiliated Hospital of Nanchang University (Nanchang, China). As diseased controls, 120 patients with lung ailments (40 pneumonia, 40 COPD, and 40 lung cancer cases), confirmed clinically after eliminating pulmonary TB, were enrolled from the First Affiliated Hospital of Nanchang University and Jiangxi Chest Hospital from July 2015 to December 2016. It should be noted that there are 52 TB patients, 21 healthy controls, 9 lung cancer patients, 7 pneumonia patients, and 10 COPD patients who enrolled in this study and overlap with the subjects of one of our previous study (Huang et al., [@B14]). All subjects with hypertension, diabetes, autoimmune diseases, a history of immunosuppressive drug use, hepatitis B, hepatitis C, or HIV infection were excluded from the analysis. This study had approval from by the Ethics Committee of the First Affiliated Hospital of Nanchang University; all participants provided signed informed consent. The protocols complied with the Declaration of Helsinki. Blood samples (5 mL) were collected from all subjects in K2-EDTA tubes and centrifuged at 2,000 g for 10 min at 4°C, followed by 12,000 g for 10 min at 4°C. The supernatants (plasma) were carefully collected and stored at −80°C until use. All specimens in this study were verified to have no hemolysis by appearance observation and determination of free hemoglobin (Hb) in plasma before the experiments. All experiments were carried out according to the Laboratory Biosafety Manual of the Clinical Laboratory of the First Affiliated Hospital of Nanchang University in a level II biological safety laboratory. With the exception of centrifugation, sample processing was performed under a level II biological safety cabinet. Before centrifugation, the samples were sealed in centrifuge tubes with screw caps.

Total RNA isolation
-------------------

Total RNA extraction from plasma specimens was carried out with miRNeasy Mini Kit (Qiagen, Germany). RNA integrity and quantity were assessed on a NanoDrop™1000 spectrophotometer (NanoDrop Technologies, USA).

Microarray analysis of circRNA level assessment
-----------------------------------------------

Six RNA specimens were assessed by KANGCHEN (Shanghai, China) using Arraystar circRNA Microarray (Arraystar Inc., Rockville, MD, USA) analysis as directed by the manufacturer. In this study, human circRNA microarray v1.0 (Arraystar Inc.) containing 5396 circular RNA probes was used. In brief, total RNA was treated with RNase R for linear RNA removal and circRNA enrichment. Upon amplification, the obtained circRNAs were submitted to transcription for fluorescent cRNA production by the random priming method. Then, the fluorescent cRNAs were hybridized onto the Arraystar Human circRNA Array. Subsequently, the arrays were scanned on Agilent G2505C Scanner. The Agilent Feature Extraction software was used for image import and raw data were extracted. Differentially expressed circRNAs between the two groups were evaluated by *t*-test, and *P*-value correction for False Discovery Rate (FDR) was carried out using the Benjamini-Hochberg (BH) procedure. An absolute fold change value ≥1.5 and FDR *P* \< 0.05 was considered statistically significant. Quantile normalization of raw data and subsequent data processing were performed with the R software limma package (version 2.7.10).

Quantitative real-time PCR analysis
-----------------------------------

The cDNAs were obtained by reverse transcription from total RNA with a PrimeScript™ RT kit (Takara Bio Inc., Japan). SYBR®Premix Ex Taq™ II (TaKaRa) was used for fluorescence quantitative real-time PCR (RT-qPCR), with GAPDH as an internal control (Yin et al., [@B35]; Zhao et al., [@B38]). Divergent primers (Supplementary Table [1](#SM1){ref-type="supplementary-material"}) were designed through the Circinteractome Divergent Primers web, verified via primer-BLAST, and synthesized by Shanghai Shenggong (Shanghai, China). RT-qPCR was performed on a ABI 7500 Real Time PCR System (Applied Biosystems, USA). The amounts of circRNAs were derived by the 2^−ΔΔ*Ct*^ method.

Statistical analysis
--------------------

Quantile normalization and subsequent data processing were performed in R. SPSS 17.0 (SPSS Inc.) was utilized for other statistics. Data are mean ± standard deviation (SD); normality was assessed by the Kolmogorov-Smirnov method. Student\'s *t*-test and Mann-Whitney *U*-test were employed to compare normally distributed parameters and those with skewed distribution, respectively. A receiver operating characteristic (ROC) curve was generated to evaluate the diagnostic value of circRNAs. The Spearman method was used for correlation analysis. The validated plasma biomarkers were entered into binary logistic regression models, and model selection was performed to determine the final combinations of biomarkers. *P* \< 0.05 was considered statistically significant.

Results {#s3}
=======

Characteristics of the study population
---------------------------------------

We first analyzed plasma circRNAs of 3 patients with active pulmonary TB and 3 healthy control individuals by circRNA microarrays. In the validation stage, 170 pulmonary TB patients, 40 pneumonia patients, 40 COPD patients, 40 lung cancer patients, and 150 healthy controls were recruited. The clinical features of all participants are presented in Table [1](#T1){ref-type="table"}.

###### 

Characteristics of study subjects in the screening and validation stage.

  **Characteristic**                   **Microarray analysis**   **Validation**                                                                                                           
  ------------------------------------ ------------------------- ---------------- ------------------------- ------------------------- ------------------------- ------------------------- -------------------------
  Enrollment time                      May, 2015                 May, 2015        June, 2015 to Jan, 2017   June, 2015 to Jan, 2017   July, 2015 to Dec, 2016   July, 2015 to Dec, 2016   July, 2015 to Dec, 2016
  Total number                         3                         3                170                       150                       40                        40                        40
  Gender (male/female)                 2/1                       2/1              115/55                    98/52                     30/10                     29/11                     28/12
  Age (years, mean)                    37.5 ± 5.4                35.8 ± 6.9       44.5 ± 15.8               42.1 ± 13.3               49.9 ± 11.0               46.1 ± 14.2               48.7 ± 16.4
  Smoking (Yes/no)                     1/2                       1/2              92/78                     85/65                     30/10                     27/13                     25/15
  BCG vaccination (yes/no)             3/0                       3/0              162/8                     143/7                     40/0                      39/1                      37/3
  TST (Positive/Negative)              3/0                       0/3              170/0                     NA                        NA                        NA                        NA
  **SIGN AND SYMPTOMS (n)**                                                                                                                                                               
  Productive or unproductive cough     3                         --               141                       --                        --                        --                        --
  Weight loss                          3                         --               134                       --                        --                        --                        --
  Fever                                3                         --               118                       --                        --                        --                        --
  **SMEAR (n)**                                                                                                                                                                           
  \+                                   1                         NA               90                        NA                        NA                        NA                        NA
  ++                                   1                         NA               28                        NA                        NA                        NA                        NA
  +++                                  1                         NA               21                        NA                        NA                        NA                        NA
  Negative                             0                         NA               31                        NA                        NA                        NA                        NA
  **STATUS OF CHEST RADIOGRAPH (n)**                                                                                                                                                      
  Minimal                              1                         NA               79                        NA                        NA                        NA                        NA
  Moderate                             1                         NA               56                        NA                        NA                        NA                        NA
  Advanced                             1                         NA               35                        NA                        NA                        NA                        NA

*NA, not applicable*.

Screening of differentially expressed circRNAs
----------------------------------------------

To assess whether circRNAs are differentially expressed between TB patients and normal subjects, plasma total RNA was extracted from 3 patients with active pulmonary TB and 3 age- and sex-matched healthy controls for circRNA microarray analysis. The box plots in Figure [1](#F1){ref-type="fig"} show the normalized intensities for the plasma samples from TB patients and healthy controls. Hierarchical clustering and scatter plots revealed group differences. Sixty-one circRNAs showed differential expression levels between TB patients and controls, including 43 and 18 that were upregulated and downregulated in TB, respectively (fold change ≥1.5; *P* \< 0.05) (Supplementary Table [2](#SM2){ref-type="supplementary-material"}). The 15 most up-regulated and down-regulated circRNAs are presented in Table [2](#T2){ref-type="table"}. The upregulated circRNAs included 36 exonic, 3 intronic, 3 sense overlapping and 1 antisense. Meanwhile, 14 exonic, 2 intronic, and 2 sense overlapping circRNAs were downregulated. To identify the most clinically applicable biomarkers, the 6 circRNAs showing the highest fold changes were selected from the upregulation group for further analysis: hsa_circ_0009024, hsa_circ_0001953, hsa_circ_0008297, hsa_circ_0003528, hsa_circ_0003524 and hsa_circ_0015879.

![Differentially expressed circRNAs in TB patients (*n* = 3) and control individuals (*n* = 3). **(A)** Hierarchical clustering of circRNA expression profiles in the TB and control groups. "Red" and "green" indicate high and low relative expression levels, respectively. **(B)** Box plots showing the distributions of circRNAs in the two groups, which were similar after normalization. **(C)** In the scatter plot, circRNAs above the top and bottom green lines indicated more than 1.5-fold change in circRNA levels between the two groups. HC, healthy controls; TB, tuberculosis.](fmicb-09-02010-g0001){#F1}

###### 

Top 30 differently expressed circRNAs in TB patients.

  **CircRNA ID**     ***P*-value**   **FDR**       **FC**    **Regulation**   **CircRNA_type**    **Strand**   **Best_transcript**   **GeneSymbol**
  ------------------ --------------- ------------- --------- ---------------- ------------------- ------------ --------------------- ----------------
  hsa_circ_0009024   4.17569E-06     0.002492284   5.32391   Up               Exonic              \+           NR_045128             TXLNGY
  hsa_circ_0001953   5.48752E-05     0.004765914   4.66648   Up               Exonic              \+           NM_003411             ZFY
  hsa_circ_0008297   0.000235706     0.007462334   4.25936   Up               Exonic              \+           NM_004660             DDX3Y
  hsa_circ_0003528   0.008851434     0.04811339    3.71021   Up               Exonic              \+           NM_021982             SEC24A
  hsa_circ_0003524   0.000648282     0.011824622   3.63670   Up               Exonic              --           NM_001009993          FAM168B
  hsa_circ_0015879   0.003051585     0.025521368   3.48609   Up               Exonic              \+           NM_000299             PKP1
  hsa_circ_0005232   0.000732236     0.012499195   2.97233   Up               Exonic              --           ENST00000403092       SLC8A1
  hsa_circ_0044234   6.90949E-05     0.005050619   2.88108   Up               Exonic              --           NM_001256             CDC27
  hsa_circ_0079262   0.002185264     0.021504814   2.59964   Up               Exonic              --           NM_024963             FBXL18
  hsa_circ_0000957   0.003127342     0.025825725   2.59498   Up               Antisense           \+           NM_017607             PPP1R12C
  hsa_circ_0006903   0.000572627     0.011232802   2.49779   Up               Exonic              --           NM_015114             ANKLE2
  hsa_circ_0059880   0.003497462     0.027589529   2.45421   Up               Exonic              \+           NM_032819             ZNF341
  hsa_circ_0051907   0.002823067     0.024494929   2.32641   Up               Sense overlapping   \+           NM_001015             RPS11
  hsa_circ_0070739   0.008585132     0.047220225   2.29498   Up               Exonic              \+           NR_109983             LOC729218
  hsa_circ_0006517   1.87953E-05     0.003817991   2.21372   Up               Exonic              \+           NM_005578             LPP
  hsa_circ_0002473   2.30534E-06     0.002191928   3.54805   Down             Exonic              \+           NM_006260             DNAJC3
  hsa_circ_0089837   0.000186077     0.006946271   3.21325   Down             Exonic              --           uc004crl.3            AK000470
  hsa_circ_0014186   3.57663E-05     0.004521709   3.00623   Down             Exonic              \+           NM_030918             SNX27
  hsa_circ_0003641   3.86525E-05     0.004540802   2.90244   Down             Exonic              \+           NM_000051             ATM
  hsa_circ_0001490   0.000018765     0.003817991   2.89995   Down             Exonic              \+           NM_004520             KIF2A
  hsa_circ_0079385   2.18594E-05     0.003841024   2.67505   Down             Exonic              \+           NM_018106             ZDHHC4
  hsa_circ_0053944   0.000673145     0.0120992     2.66694   Down             Exonic              --           uc002roz.1            FAM98A
  hsa_circ_0048764   0.000885593     0.013511581   2.45421   Down             Exonic              \+           NM_015414             RPL36
  hsa_circ_0092360   7.09269E-05     0.005055373   2.20000   Down             Intronic            \+           ENST00000422514       RPL23A
  hsa_circ_0003748   0.000163961     0.006608264   2.11369   Down             Exonic              --           NM_016291             IP6K2
  hsa_circ_0000745   0.000339836     0.008957861   2.02089   Down             Exonic              \+           NM_152904             SPECC1
  hsa_circ_0000601   0.001165123     0.015424823   1.74041   Down             Exonic              --           NM_017672             TRPM7
  hsa_circ_0000169   0.000178628     0.006792563   1.73952   Down             Sense overlapping   \+           NM_133494             NEK7
  hsa_circ_0002228   2.30882E-05     0.003841024   1.62324   Down             Exonic              --           NM_001101426          ISPD
  hsa_circ_0092283   0.001758672     0.019370551   1.60165   Down             Intronic            --           ENST00000216181       MYH9

*CircRNA ID, The circRNA ID is in circBase (<http://www.circbase.org/>)*.

Validation of circRNAs expression
---------------------------------

Microarray data were validated by RT-qPCR analysis of hsa_circ_0009024, hsa_circ_0001953, hsa_circ_0008297, hsa_circ_0003528, hsa_circ_0003524 and hsa_circ_0015879, in an independent cohort of 50 TB patients and 50 normal subjects. A good consistency between microarray and RT-qPCR data was obtained (Figure [2](#F2){ref-type="fig"}), as the levels of these 6 circRNAs were significantly increased in the TB patients.

![Validation of circRNA microarray profiles by RT-qPCR. The expression levels of six circRNAs were validated by RT-qPCR in plasma specimens from an independent cohort consisting of 50 TB patients and 50 healthy controls. The relative expression levels of circRNAs were normalized to GAPDH. Data are mean ± SD. Statistical analysis was performed by the nonparametric Mann-Whitney *U* test.](fmicb-09-02010-g0002){#F2}

ROC curve analysis of differentially expressed circRNAs
-------------------------------------------------------

To assess the diagnostic value of these confirmed plasma circRNAs as candidate biomarkers of TB, we performed ROC curve analysis. As shown in Figure [3](#F3){ref-type="fig"}, AUC values were larger than 0.500 for all 6 candidate circRNAs, suggesting their potential diagnostic value. Notably, the AUC for hsa_circ_0001953 reached 0.856 (\[0.782--0.930\], *P* \< 0.001), and was the largest among the 6 circRNAs. The other AUC values were 0.808 (\[0.721--0.894\], *P* \< 0.001) for hsa_circ_0009024, 0.768 (\[0.672--0.864\], *P* \< 0.001) for hsa_circ_0003528, 0.715 (\[0.613--0.816\], *P* \< 0.001) for hsa_circ_0003524, 0.692 (\[0.589--0.795\], *P* \< 0.001) for hsa_circ_0008297 and 0.676 (\[0.570--0.782\], *P* = 0.002) for hsa_circ_0015879. Sensitivities and specificities of all circRNAs were obtained based on respective cut-off values (Table [3](#T3){ref-type="table"}).

![ROC curve analysis of confirmed circRNAs in plasma samples from TB patients in the validation set. TB group, *n* = 50; HC group, *n* = 50. AUC values are provided on the graphs.](fmicb-09-02010-g0003){#F3}

###### 

Sensitivity and specificity of the candidate biomarkers in controls and TB patients.

  **Candidate biomarkers**   **AUC (95% CI)**       **Sensitivity (%) (95% CI)**   **Specificity (%) (95% CI)**   ***P*-value**   **Cut-off value**
  -------------------------- ---------------------- ------------------------------ ------------------------------ --------------- -------------------
  hsa_circ_0009024           0.808 (0.721--0.894)   70.00 (55.39--82.14)           80.00 (66.28--89.97)           \< 0.0001       1.625
  hsa_circ_0001953           0.856 (0.782--0.930)   74.00 (59.65--85.37)           90.00 (78.19--96.67)           \< 0.0001       1.760
  hsa_circ_0003528           0.768 (0.672--0.864)   76.00 (61.83--86.94)           74.00 (59.65--85.37)           \< 0.0001       1.275
  hsa_circ_0008297           0.692 (0.589--0.795)   50.00 (35.53--74.47)           88.00 (75.69--95.47)           0.0009          1.365
  hsa_circ_0003524           0.715 (0.613--0.816)   62.00 (47.18--75.35)           78.00 (64.04--88.47)           0.0002          1.245
  hsa_circ_0015879           0.676 (0.570--0.782)   52.00 (37.42--66.34)           80.00 (66.28--89.97)           0.0024          1.335

Plasma circRNA amounts are associated with the severity of TB
-------------------------------------------------------------

TB cases were grouped in 3 groups as specified in Materials and Methods (minimal, moderate, and advanced disease). Then, associations of circRNA levels with the radiological score (severity index) were determined by the Spearman\'s rank correlation test. As depicted in Figure [4](#F4){ref-type="fig"}, 3 of the 6 circRNAs showed significant associations with the radiological score. Among these circRNAs, hsa_circ_0009024 and hsa_circ_0001953 were moderately correlated with disease severity, while hsa_circ_0008297 showed a weak correlation. Meanwhile, hsa_circ_0003528, hsa_circ_0003524 and hsa_circ_0015879 showed no associations with the radiological score. Considering the above findings, hsa_circ_0001953 and hsa_circ_0009024 were selected as potential biomarkers for TB diagnosis.

![Associations of circRNA levels with lung injury in TB patients. Lung injury in TB patients was classified in a double-blind manner into three grades. Images are representative of minimal (1) (*n* = 25), moderate (2) (*n* = 15), and advanced (3) (*n* = 10) disease stages. The levels of six circRNAs were associated with the degree of lung injury in patients with active TB as assessed by the Spearman\'s rank correlation test. *P*- and *r*-values are specified in each chart.](fmicb-09-02010-g0004){#F4}

Clinical confirmation of TB biomarkers
--------------------------------------

The diagnostic potential of hsa_circ_0001953 and hsa_circ_0009024 in the clinical setting was determined by testing these circRNAs in a completely different sample comprising 120 TB and 100 healthy control subjects. Compared with healthy controls, the plasma levels of hsa_circ_0001953 and hsa_circ_0009024 were significantly higher in TB patients (Figure [5A](#F5){ref-type="fig"}, Supplementary Table [3](#SM3){ref-type="supplementary-material"}). The AUC for hsa_circ_0001953 was 0.826 (\[0.770--0.881\], *P* \< 0.001), indicating sensitivity and specificity of 69.17 and 89.00%, respectively. For hsa_circ_0009024, an AUC of 0.777 (\[0.716--0.838\], *P* \< 0.001) was obtained; sensitivity and specificity were 60.00 and 86.00%, respectively. When hsa_circ_0001953 and hsa_circ_0009024 were combined, the AUC increased to 0.915 (\[0.880--0.951\], *P* \< 0.001), with sensitivity and specificity of 72.50 and 96.00%, respectively (Figure [5B](#F5){ref-type="fig"}).

![ROC curve analysis of hsa_circ_0009024 combined with hsa_circ_0001953. **(A)** Expression levels of hsa_circ_0009024 and hsa_circ_0001953 in TB patients (*n* = 120) and controls (*n* = 100). **(B)** ROC curves of hsa_circ_0009024 and hsa_circ_0001953 for discriminating between active TB patients and healthy controls. AUC values are given on the graphs.](fmicb-09-02010-g0005){#F5}

Hsa_circ_0001953 and hsa_circ_0009024 expression levels in patients with TB, COPD, pneumonia, and lung cancer
-------------------------------------------------------------------------------------------------------------

As shown in Figure [6](#F6){ref-type="fig"}, hsa_circ_0001953 and hsa_circ_0009024 amounts were markedly increased in the TB group in comparison with COPD, pneumonia and lung cancer patients (all *P* \< 0.001), respectively; however, the COPD, pneumonia, and lung cancer groups showed similar values (*P* \> 0.05).

![RT-qPCR assay validation of hsa_circ_0009024 and hsa_circ_0001953 expression levels in plasma specimens from 120 TB patients vs. 40 pneumonia, 40 COPD and 40 lung cancer patients, respectively. One-way ANOVA was used for statistical analysis.](fmicb-09-02010-g0006){#F6}

Next, a risk score based on hsa_circ_0001953 combined with hsa_circ_0009024 from the clinical validation set was further assessed in TB patients and all controls (healthy controls in the validation set, as well as COPD, pneumonia and lung cancer patients). The AUC for the latter risk score was 0.909 (\[0.876--0.942\], *P* \< 0.001), with sensitivity and specificity of 80.00 and 87.73%, respectively (Figure [7A](#F7){ref-type="fig"}). This risk score also significantly discriminated the patients with TB from diseased controls (COPD, pneumonia and lung cancer patients), with an AUC of 0.897 (\[0.858--0.937\], *P* \< 0.001); sensitivity and specificity were 79.17 and 86.67%, respectively (Figure [7B](#F7){ref-type="fig"}).

![ROC curve analysis of hsa_circ_0009024 combined with hsa_circ_0001953 for determining risk-scores in **(A)** TB patients in the validation set vs. all controls (healthy controls in the validation set, as well as pneumonia, COPD, and lung cancer patients), **(B)** TB patients in the validation set vs. pneumonia, COPD, and lung cancer patients. AUC values are given on the graphs.](fmicb-09-02010-g0007){#F7}

Hsa_circ_0001953 and hsa_circ_0009024 expression levels are markedly decreased in TB patients upon successful therapy
---------------------------------------------------------------------------------------------------------------------

In this study, hsa_circ_0001953 and hsa_circ_0009024 amounts were assessed in 25 TB cases pre- and post-treatment. In comparison with pre-treatment amounts, hsa_circ_0001953 and hsa_circ_0009024 showed lower values upon anti-TB therapy (Figure [8](#F8){ref-type="fig"}). Indeed, average hsa_circ_0001953 and hsa_circ_0009024 amounts returned almost to control values upon treatment, with the control and treated TB patients showing similar values (*P* \> 0.05).

![Changes in hsa_circ_0009024 and hsa_circ_0001953 levels in response to therapy. The levels of hsa_circ_0009024 and hsa_circ_0001953 were assessed by RT-qPCR. The dot plot shows relative levels of hsa_circ_0009024 and hsa_circ_0001953 in the same patients before and after treatment completion (*n* = 25). The relative levels of hsa_circ_0009024 and hsa_circ_0001953 in healthy controls (*n* = 50), pulmonary TB patients before (*n* = 25) and after treatment (*n* = 25) were plotted. Healthy controls and treated TB patients showed similar values. Statistical analysis was performed by Student\'s *t*-test.](fmicb-09-02010-g0008){#F8}

Moreover, in our previous studies, we found that hsa_circ_0009024 was also significantly elevated in PBMCs from TB patients (Huang et al., [@B14]). We conducted Spearmen correlation analysis to explore the correlation between levels of hsa_circ_0009024 expression in plasma and in the corresponding PBMCs of the same patients. A moderate correlation was observed for hsa_circ_0009024 (*r*~*s*~ = 0.5449, *P* = 0.0022; Figure [9](#F9){ref-type="fig"}).

![Spearman\'s rank correlation scatter plot of hsa_circ_0009024 levels in PBMCs samples and plasma.](fmicb-09-02010-g0009){#F9}

CircRNA/miRNA interaction analysis
----------------------------------

CircRNAs may function as miRNA sponge to bind miRNAs and regulate expression of target genes. To evaluate the functions of hsa_circ_0001953 and hsa_circ_0009024, potential miRNA targets of the circRNAs were searched using the Arraystar\'s home-made miRNA target prediction software. The details of the molecular interactions between these two circRNAs and above target miRNAs are depicted in Figure [10](#F10){ref-type="fig"}.

![A snippet of the detailed annotation for circRNA/miRNA interaction. **(A)** hsa_circ_0009024. **(B)** hsa_circ_0001953. The circRNA/miRNA interaction was predicted with Arraystar\'s home-made miRNA target prediction software. Binding sites of conserved miRNAs with good mirSVR scores are represented.](fmicb-09-02010-g0010){#F10}

Discussion {#s4}
==========

CircRNAs are newly discovered endogenous non-coding RNAs featuring structural stability, high abundance, and tissue-specificity. To date, studies have revealed the promising role of circRNAs as biomarkers of tumors (He et al., [@B12]), cardiovascular disease (Fan et al., [@B8]), Alzheimer\'s disease (Lukiw, [@B22]), and other diseases (Chen et al., [@B5]; Tang et al., [@B31]). Recently, Qian et al. identified seven circRNAs (hsa_circ_0000414, hsa_circ_0000681, hsa_circ_0002113, hsa_circ_0002362, hsa_circ_0002908, hsa_circ_0008797, hsa_circ_0063179) have the potential to serve as novel potential biomarkers for diagnosis of active TB (Qian et al., [@B27]). Zhuang et al. showed that hsa_circ_0005836 in PBMCs might serve as a novel potential biomarker of TB infection (Zhuang et al., [@B39]). Our previous study revealed that several PBMC circRNAs can be used as potential biomarkers for TB (Huang et al., [@B13], [@B14]). However, due to the complexity of RNA extraction from PBMCs and challenging quality control, it is difficult to meet the needs for clinical application. Here, circRNA amounts in plasma specimens from active TB patients and healthy subjects were assessed by circRNA microarray.

As shown above, 43 upregulated and 18 downregulated circRNAs were found by microarrays in the TB group. To identify clinically relevant biomarkers, 6 significantly overexpressed circRNAs were identified, and associations of their amounts with TB severity were evaluated. The validation study demonstrated that plasma amounts of these 6 circRNAs (hsa_circ_0009024, hsa_circ_0001953, hsa_circ_0008297, hsa_circ_0003528, hsa_circ_0003524 and hsa_circ_0015879) were remarkably increased in the TB patients analyzed. ROC curve analysis suggested that hsa_circ_0001953 had a significant value for TB diagnosis, followed by hsa_circ_0009024, hsa_circ_0003528, hsa_circ_0003524, hsa_circ_0008297, and hsa_circ_0015879. Furthermore, Spearman\'s rank correlation analysis revealed that hsa_circ_0001953 and hsa_circ_0009024 amounts were moderately correlated with the radiological score, implying that hsa_circ_0001953 and hsa_circ_0009024 might be involved in TB pathology.

To determine whether hsa_circ_0001953 and hsa_circ_0009024 could constitute diagnostic biomarkers of TB, they were assessed in larger patient cohorts. Based on ROC curves, cut-off values that best differentiated TB patients from healthy individuals were selected. Hsa_circ_0001953 had a sensitivity of 69.17% and a specificity of 89.00% for TB, while hsa_circ_0009024 had sensitivity and specificity of 60.00 and 86.00%, respectively. Hsa_circ_0001953 demonstrated a higher discriminating ability compared with hsa_circ_0009024, although not statistically significant (*P* \> 0.05). ROC analysis using both targets in combination yielded an increased AUC of 0.915, with 72.50% sensitivity and 96.00% specificity in discriminating TB patients from normal controls, indicating additive effects in diagnostic potential of the two circRNAs. These diagnostic abilities were quite comparable to those reported for blood biomarkers of TB, especially in terms of specificity (Fu et al., [@B9]; Miotto et al., [@B24]; Zhang et al., [@B36]; Latorre et al., [@B18]). Next, the ability of the combination to effectively segregate TB from other lung ailments (COPD, pneumonia, and lung cancer) was assessed. As shown above, hsa_circ_0001953 and hsa_circ_0009024 might constitute TB signature circRNAs and represent potential TB biomarkers. Moreover, the levels of hsa_circ_0001953 and hsa_circ_0009024 in TB patients returned to normal after effective therapy.

In one of our previous study, we found that the levels of hsa_circ_0009024 were also significantly elevated in PBMCs from TB patients compared to those of healthy control (Huang et al., [@B14]). In that study we detected the levels of circRNAs only in PMBCs, but not in plasma. While the subjects recruited in these two studies were not the same, there were 52 TB patients and 21 healthy controls overlapped. Thus, the levels of hsa_circ_0009024 were detected in both PBMCs and plasma in these overlapped subjects. Combining the results of these two studies we found that the levels of hsa_circ_0009024 in plasma were moderately correlated with those in PBMCs. Although further confirmation needed these results suggest that PBMCs may secrete circRNAs to the plasma. In conformity with our findings, Li et al. recently reported that hsa_circ_0001017 and hsa_circ_0061276 can be secreted from gastric cancer cells (Li et al., [@B20]). However, the level of another circRNA, hsa_circ_0001953, which was found to increase significantly in plasma, had no significant difference in the PBMCs between TB patients and healthy controls (Huang et al., [@B14]), which suggested that other cells may also secret circRNAs into plasma.

It is known circRNAs might function as miRNA sponges or regulate parent genes to alter the disease course (Ebbesen et al., [@B7]; Greene et al., [@B11]). Multiple miRNAs regulate immune responses to infection by mycobacteria (Abdalla et al., [@B2]; Bettencourt et al., [@B4]; Sabir et al., [@B30]). For instance, miR-125b reduces TNF amounts via direct binding to its 3′UTR (Rajaram et al., [@B28]), whereas miR-21 suppresses IL-12 synthesis via IL-12p35 inhibition, impairing responses to Mycobacterium (Wu et al., [@B34]). *Mycobacterium*-induced miR-155 targets Rheb to enhance autophagy in macrophages, which in turn promote the elimination of intracellular bacilli (Wang et al., [@B32]). Iwai et al. found miRNA-155 knockout mice show increased susceptibility to *M. tuberculosis* compared with wild-type animals (Iwai et al., [@B15]). Bioinformatics predicted that miR-767-5p, miR-1298-3p, miR-132-3p, miR-885-5p, and miR-196a-5p might be potential targets of hsa_circ_0001953. Hsa_circ_0009024 was shown to potentially bind miR-6844, miR-1248, miR-141-5p, miR-545-5p, and miR-95-5p. A previous study demonstrated that *M. tuberculosis* decreases human macrophage IFN-γ responsiveness through miR-132 (Ni et al., [@B26]). However, due to the limited knowledge of miRNA and circRNA properties, the potential functions of the circRNA-miRNA axis in the pathogenesis of TB require further investigation.

However, the current study had many limitations. First, because of the policy of universal BCG vaccination in China, it is very challenging to recruit control subjects with negative TST. Meanwhile, because IGRA has not been popularized in China due to its high cost (\~110 USD/test), we did not assess control subjects for latent TB in this study. In addition, the subjects were limited to the Chinese Han population, and only 25 TB patients completed follow-up. Therefore, the current findings require confirmation in larger and more diverse samples.

In addition, a fact we cannot avoid is that as a new biomarker for disease diagnosis, the consistency or reproducibility of circRNA in different studies is not satisfactory. Due to the fact that the expression of circRNA is influenced by many factors, such as the specimen type, detection technology and individual difference, the candidate circRNAs obtained in different laboratories are often different, even targeting the same disease. We noticed that the circRNAs with potential to serve as biomarker for TB diagnosis in this study (hsa_circ_0001953 and hsa_circ_0009024) are different from the candidate circRNAs obtained by Qian et al. ([@B27]). By comparing these two studies, we speculate that the inconsistent result might result from four main differences between these two studies. First, the specimen we studied is plasma, not PBMCs in Qian\'s study (Qian et al., [@B27]). Second, we screened the differentially expressed circRNAs by circRNA expression microarray, while Qian et al. characterized the circRNA expression profile firstly by using RNA sequencing, followed by circRNA expression microarrays. As we know, the data obtained by RNA sequencing is far bigger and more complex than circRNA expression microarrays. Third, the differentially expressed circRNA was screened with criterion of \>1.5-fold change and a *P*-value \< 0.05, which was more harsh than the criterion in Qian\'s study. A *P*-value \< 0.05 were deemed differentially expressed in Qian\'s study (Qian et al., [@B27]). Finally, the differentially expressed circRNAs chosen for validation were restricted in 5 given KEGG pathways, those were "Cytokine-cytokine receptor interaction," "Chemokine signaling pathway," "Fc gamma R-mediated phagocytosis," "Neurotrophin signaling pathway," and "Bacterial invasion of epithelial cells." However, the 6 circRNAs showing the highest fold changes were chosen from the up-regulation group for validation and further analysis in this study.

Overall, differentially expressed circRNAs were detected in plasma specimens from active TB and normal control patients. Our data indicated that hsa_circ_0001953 and hsa_circ_0009024 levels in plasma could constitute new diagnostic biomarkers for TB diagnosis. Comprehensive studies are warranted to unveil the mechanisms by which circRNAs affect TB infection. And, considering the inconsistency of the findings between different laboratories, a more rigorous, large sample and multicenter study is needed to further confirm the reliability and reproducibility of these circRNAs in TB diagnosis.
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TB

:   tuberculosis

circRNAs

:   (circRNAs)

AFB

:   acid-fast bacilli

PBMCs

:   peripheral blood mononuclear cells

ceRNAs

:   competing endogenous RNAs

miRNAs

:   microRNAs

FDR

:   false discovery rate

SD

:   standard deviation

ROC

:   receiver operating characteristic

AUC

:   area under curve

RT-qPCR, quantitative real-time polymerase chain reaction, GAPDH

:   glyceraldehyde-3-phosphate dehydrogenase

COPD

:   chronic obstructive pulmonary disease

BCG

:   Bacille Calmette-Guérin

TST

:   tuberculin skin test

NA

:   not applicable

IGRA

:   Interferon gamma release assay.
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